Cantor Fitzgerald Maintains Overweight on Novavax, Raises Price Target to $272
Cantor Fitzgerald analyst Charles Duncan maintains Novavax (NASDAQ:NVAX) with a Overweight and raises the price target from $217 to $272.
Novavax’s COVID-19 Vaccine, Flu Shot Co-administration Preserved Efficacy, Likely ‘Viable Strategy,’ Company Says
Novavax Inc (NASDAQ:NVAX) announced its experimental COVID-19 vaccine remained effective when coadministered with an approved flu shot. Researchers are interested in…
Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
COVID-19 vaccine candidate efficacy in those 18 to <65 years old was preserved in influenza vaccine recipients
- Influenza vaccine immunogenicity preserved
- Study demonstrated no early safety concerns
- Data
Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up
It was "better late than never" for Novavax, Inc. (NASDAQ: NVAX), as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.
Why Novavax, Orphazyme, Avenue Therapeutics Shares Are Moving Monday
Novavax, Inc. (NASDAQ: NVAX), Orphazyme A/S (NASDAQ: ORPH) and Avenue Therapeutics, Inc.
Why Novavax Stock Is Moving Today
Novavax, Inc. (NASDAQ: NVAX) shares are trading higher by 9.8% at $230.25 Monday morning after the company announced positive Phase 3 trial results for its COVID-19 vaccine.
Long-awaited Novavax’s COVID-19 Vaccine Results Hit 90% Efficacy In Pivotal US Trial, 100% Efficacy Against Moderate, Severe Infection
Novavax Inc (NASDAQ:NVAX) has finally completed its U.S. Phase 3 trial for its protein-based COVID-19 vaccine candidate. Overall efficacy in the…
Novavax’s COVID-19 Vaccine Candidate Showed Immune Response, Protection Against Variants
Novavax Inc (NASDAQ:NVAX) announced preclinical and clinical data on its recombinant protein COVID-19 vaccine candidate, NVX-CoV2373, directed against the SARS-CoV-2 Beta…